Mark Sabag - 27 Jan 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, International Markets Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol: TEVA
Transactions as of: 27 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 29 Jan 2026, 16:04:26 UTC
Previous filing: 11 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sabag Mark	Executive Vice President, International Markets Commercial	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	29 Jan 2026	0001721442

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award	$0	+141,478		$0.000000	141,478	27 Jan 2026	Ordinary Shares	141,478		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, International Markets Commercial